The effects of bivalent human papillomavirus (HPV) vaccination on high-risk anogenital HPV infection among sexually active female adolescents with and without perinatally acquired HIV
Issued Date
2023-11-16
Resource Type
ISSN
14485028
eISSN
14498987
DOI
Scopus ID
2-s2.0-85184665939
Pubmed ID
37967583
Journal Title
Sexual Health
Volume
21
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Sexual Health Vol.21 No.1 (2023)
Suggested Citation
Ounchanum P., Achalapong J., Teeraananchai S., Gatechompol S., Phongsamart W., Chokephaibulkit K., Tran D.N.H., Dang H.L.D., Teeratakulpisarn N., Chalermchockcharoenkit A., Singtoroj T., Sohn A.H., Phanuphak N. The effects of bivalent human papillomavirus (HPV) vaccination on high-risk anogenital HPV infection among sexually active female adolescents with and without perinatally acquired HIV. Sexual Health Vol.21 No.1 (2023). doi:10.1071/SH22185 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97578
Title
The effects of bivalent human papillomavirus (HPV) vaccination on high-risk anogenital HPV infection among sexually active female adolescents with and without perinatally acquired HIV
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background. Females with perinatal HIV (PHIV) infection are at elevated risk for anogenital high-risk human papillomavirus (HR-HPV) infection. Limited data are available around the effect of the HPV vaccination after initiation of sexual activity among PHIV youth. This study aims to assess the impact of a bivalent HPV vaccination on the persistence of anogenital HR-HPV among sexually active female PHIV youth and matched HIV-negative controls aged 12–24 years in Thailand and Vietnam. Methods. During a 3-year study, prevalent, incident, and persistent HR-HPV infection were assessed at annual visits. A subset of participants received a bivalent HPV vaccine. Samples were taken for HPV testing from the vagina, cervix, and anus. HR-HPV persistence was defined as the detection of the same genotype(s) at any anogenital compartment over ≥ two consecutive visits. Results. Of the 93 PHIV and 99 HIV-negative female youth enrolled in this study, 25 (27%) PHIV and 22 (22%) HIV-negative youth received a HPV vaccine. Persistent infection with any HR-HPV type was significantly lower among PHIV youth who received the vaccine compared to those who did not (33% vs 61%, P = 0.02); a difference was not observed among HIV-negative youth (35% vs 50%, P = 0.82). PHIV infection (adjusted prevalence ratio [aPR] 2.31, 95% CI 1.45–3.67) and not receiving a HPV vaccine (aPR, 1.19, 95%CI 1.06–1.33) were associated with persistent anogenital HR-HPV infection. Conclusions. Bivalent HPV vaccination after initiation of sexual activity was associated with reduced persistence of anogenital HR-HPV infection in Southeast Asian PHIV female youth, which may be related to vaccine cross-protection. Primary and catch-up HPV vaccinations should be prioritised for children and youth with HIV.